You are here

  • Home
  • Archive
  • Volume 6, Issue 10
  • IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial

Article metrics

Article menu

Download PDFPDF

XML
Cardiovascular medicine
Protocol
IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial

 

Online download statistics by month:

Online download statistics by month: January 2018 to October 2024

AbstractFullPdf
Jan 201821216
Feb 201830309
Mar 2018454213
Apr 2018191911
May 201832308
Jun 201830168
Jul 201818166
Aug 2018413314
Sep 2018141016
Oct 2018202010
Nov 2018995
Dec 2018662
Jan 20191085
Feb 2019989
Mar 2019171717
Apr 2019161414
May 2019101012
Jun 201910109
Jul 2019202013
Aug 2019101010
Oct 201920188
Nov 2019121210
Dec 201937336
Jan 202032319
Feb 202017148
Mar 2020181412
May 2020151524
Jun 20207710
Jul 202011710
Aug 202022227
Sep 2020312522
Oct 202028288
Nov 2020454122
Dec 2020201817
Jan 202113913
Feb 202110614
Mar 202110105
Apr 2021221516
May 2021774
Jun 2021161610
Jul 202112128
Aug 2021303012
Sep 2021161616
Oct 2021202019
Nov 20217713
Dec 202115159
Jan 2022232216
Feb 202218175
Mar 2022171810
Apr 2022252312
May 2022212015
Jun 2022202014
Jul 2022181812
Aug 202228279
Sep 2022201411
Oct 2022202221
Nov 2022141210
Dec 20221083
Jan 202312124
Feb 202315155
Mar 202318129
Apr 202315137
May 2023131314
Jun 202312123
Jul 2023101212
Aug 2023212112
Sep 202323177
Oct 202324104
Nov 202312135
Dec 202325259
Jan 202423237
Feb 202415158
Mar 2024282816
Apr 202415137
May 20241041058
Jun 202415158
Jul 2024726210
Aug 2024212217
Sep 202412105
Oct 2024310
Total16221487824